Trial · NCT07152782
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
NCT07152782, Phase 2, Recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis. Trials, record NCT07152782. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07152782
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
- NCT number
- NCT07152782
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 202 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
- Interventions
- Neratinib, Trastuzumab Deruxtecan
- First posted
- 2025-09-03
- Last updated
- 2026-09-28
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival(PFS) | 24 months | Time to progressive disease (according to RECIST1.1) |
| Secondary | CNS Progression-free survival (CNS-PFS) | 24 months | Time from enrollment to the first radiographic documented disease progression (PD) of all CNS target lesions (RANO-BM criteria) or death from any cause without progression was recorded. |
| Secondary | Objective response rate (ORR) | 24 months | Partial response is defined as a decrease by 30% or more in sums of longest diameter of measurable target lesions |
| Secondary | CNS Objective response rate (CNS-ORR) | 24 months | The proportion of patients with complete response (CR) and partial response (PR) evaluated as the best response observed from enrollment to progression of all CNS target lesions assessed according to RANO-BM criteria among the total number of patients who could be evaluated. |
| Secondary | Overall survival (OS) | 48 months | Time from the enrollment to death of any cause |
| Secondary | Safety and Tolerability | 24 months | Safety and Tolerability Will be Assessed According to Standard (CTCAE Version 5.0) Toxicity Reporting Criteria. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07152782
GET https://conductscience.org/api/trials/v1/NCT07152782/registered